Trial TCTR20211102003
Publication Bruminhent J, Am J Transplant, 2022
Primary outcome on the report: Seroconversion rate of the anti-SARS-CoV-2 RBD IgG antibody levels at 2 weeks after an additional dose of each COVID-19 vaccine.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.